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A 58-year-old lifetime nonsmoking woman presented with a 6-month history of cough and was found to have 
a malignant pleural effusion. Diagnostic investigations 
revealed metastatic non–small-cell lung cancer (NSCLC) 
involving the left lower lung with pleural, nodal, and skeletal 
metastasis. Histologic examination conﬁrmed a cytokeratin 
7-positive and thyroid transcription factor-1 (TTF1)-positive 
adenocarcinoma. Molecular testing revealed a deletion in 
exon 19 of the epidermal growth factor receptor (EGFR) 
gene. She had no signiﬁcant past history and was on no regu-
lar medications.
She was enrolled onto the ﬁrst-line expansion cohort 
of the Phase I, Open-Label, Multicentre Study to Assess 
the Safety, Tolerability, Pharmacokinetics and Preliminary 
Anti-tumour Activity of Ascending Doses of AZD9291 in 
Patients with Advanced Non Small Cell Lung Cancer who 
have Progressed Following Prior Therapy with an Epidermal 
Growth Factor Receptor Tyrosine Kinase Inhibitor Agent 
AURA - AZD9291 First Time in Patients Ascending Dose 
study, which treated EGFR-mutant NSCLC patients with 
AZD9291, a third generation tyrosine kinase inhibitor (TKI) 
at a dose of 160 mg daily. As part of the screening, ophthal-
mological assessment was performed, and no abnormalities 
were detected.
Five months after commencing AZD9291, she devel-
oped intermittent dry and itchy eyes consistent with kerato-
conjunctivitis sicca requiring topical lubricating solution for 
symptom relief (Fig. 1).
Restaging computed tomography scans after 3 months 
of treatment showed a partial response with reduction in size 
of the left lung mass and nodal metastases. Her pulmonary 
symptoms resolved, and she was able to resume working 
without any impingement on her functional status. Her inter-
mittent keratoconjunctivitis sicca remained her only toxicity, 
but this was managed effectively with ophthalmic moistur-
izing drops.
Given ongoing issues with keratoconjunctivitis 8 months 
after commencement, further ophthalmological examination 
was performed. Vortex keratopathy or corneal verticillata 
were noted bilaterally with mild corneal deposits at the level 
of the basal epithelium in a whorl pattern, a classic feature of 
this condition.1
Vortex keratopathy is a condition characterized by 
corneal deposits in a whorl or vortex pattern.1 It is most 
often associated with amphiphilic medications, such as 
amiodarone, and chloroquine or metabolic disorders, such 
as Fabry’s disease.2,3 There are few reported cases of vortex 
keratopathy in patients receiving TKIs such as vandetanib 
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fIGURE 1. Corneal imaging 8 months after commencement 
of AZD9291 showing pigmented whorl-like pattern of grayish 
golden-brown deposits in the corneal epithelium (marked 
with black arrows).
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and suramin (a drug used to treat sleeping sickness).4,5 The 
underlying mechanism has been postulated to involve abro-
gation of normal corneal epithelial cell migration, a process 
dependent on epidermal growth factor signaling, although 
others have suggested its pathogenesis is related to the depo-
sition of drug metabolites.
In view of the temporality of the development of 
vortex keratopathy with AZD9291, we postulate that this 
condition developed secondary to this novel TKI. In our 
patient, the keratopathy did not affect vision, and the 
patient was able to continue AZD9291 with concomitant 
topical lubricants.
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